LB Pharmaceuticals, a Phase 3-ready biotech developing therapies for neuropsychiatric diseases, raised $285 million in an upsized IPO by offering 19 million shares at $15, the midpoint of the $14 to $16 range. The New York, NY-based company originally filed to offer 16.7 million shares.
LB Pharmaceuticals plans to list on the Nasdaq under the symbol LBRX. Leerink Partners, Piper Sandler, and Stifel acted as joint bookrunners on the deal.
